DE60218751D1 - Antitumor-zusammensetzungen enthaltend taxan-derivate - Google Patents

Antitumor-zusammensetzungen enthaltend taxan-derivate

Info

Publication number
DE60218751D1
DE60218751D1 DE60218751T DE60218751T DE60218751D1 DE 60218751 D1 DE60218751 D1 DE 60218751D1 DE 60218751 T DE60218751 T DE 60218751T DE 60218751 T DE60218751 T DE 60218751T DE 60218751 D1 DE60218751 D1 DE 60218751D1
Authority
DE
Germany
Prior art keywords
compositions containing
antitumor compositions
taxan derivatives
derivatives
containing taxan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60218751T
Other languages
English (en)
Other versions
DE60218751T2 (de
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE60218751D1 publication Critical patent/DE60218751D1/de
Application granted granted Critical
Publication of DE60218751T2 publication Critical patent/DE60218751T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60218751T 2001-03-21 2002-03-21 Antitumor-zusammensetzungen enthaltend taxan-derivate Expired - Lifetime DE60218751T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives
US813018 2001-03-21
PCT/IB2002/000853 WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Publications (2)

Publication Number Publication Date
DE60218751D1 true DE60218751D1 (de) 2007-04-19
DE60218751T2 DE60218751T2 (de) 2007-11-22

Family

ID=25211230

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218751T Expired - Lifetime DE60218751T2 (de) 2001-03-21 2002-03-21 Antitumor-zusammensetzungen enthaltend taxan-derivate

Country Status (19)

Country Link
US (1) US6441026B1 (de)
EP (1) EP1478355B1 (de)
JP (1) JP4467885B2 (de)
CN (2) CN1536995A (de)
AT (1) ATE355837T1 (de)
AU (1) AU2002244877B2 (de)
BR (1) BR0208274A (de)
CA (1) CA2440160C (de)
CY (1) CY1106582T1 (de)
DE (1) DE60218751T2 (de)
DK (1) DK1478355T3 (de)
EA (1) EA006878B1 (de)
ES (1) ES2282400T3 (de)
HU (1) HUP0500478A2 (de)
IL (1) IL157992A (de)
MX (1) MXPA03008539A (de)
PT (1) PT1478355E (de)
SI (1) SI1478355T1 (de)
WO (2) WO2002074289A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
KR20050000544A (ko) * 2002-05-17 2005-01-05 아방티 파르마 소시에테 아노님 유방암 및 난소암의 보조 요법에서도세탁셀/독소루비신/사이클로포스파미드의 용도
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN104800856A (zh) * 2007-04-10 2015-07-29 日东电工株式会社 多功能聚谷氨酸盐药物载体
WO2008141111A2 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Polymers conjugated with platinum drugs
EP2155255B1 (de) 2007-05-09 2013-08-14 Nitto Denko Corporation Zusammensetzungen, die eine hydrophobe Verbindung und ein Polyaminosäurekonjugat beinhalten
JP2010526917A (ja) * 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
CN107158389A (zh) 2010-03-29 2017-09-15 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
CA2817219A1 (en) * 2010-11-12 2012-05-18 Endocyte, Inc. Methods of treating cancer
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU2005692A (en) 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5284865A (en) 1991-09-23 1994-02-08 Holton Robert A Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (de) * 1998-08-20 2000-03-01 Aventis Pharma S.A. Neue Verwendung von Taxoidverbindungen

Also Published As

Publication number Publication date
BR0208274A (pt) 2004-07-13
CA2440160A1 (en) 2002-09-26
MXPA03008539A (es) 2004-08-11
EA200301047A1 (ru) 2004-06-24
EA006878B1 (ru) 2006-04-28
US20020031505A1 (en) 2002-03-14
ATE355837T1 (de) 2007-03-15
CN101590057A (zh) 2009-12-02
JP4467885B2 (ja) 2010-05-26
EP1478355A2 (de) 2004-11-24
DK1478355T3 (da) 2007-07-02
SI1478355T1 (sl) 2007-08-31
JP2004536790A (ja) 2004-12-09
EP1478355B1 (de) 2007-03-07
PT1478355E (pt) 2007-05-31
CA2440160C (en) 2011-07-05
WO2002074289A3 (en) 2004-09-02
DE60218751T2 (de) 2007-11-22
AU2002244877B2 (en) 2006-07-20
IL157992A (en) 2008-08-07
ES2282400T3 (es) 2007-10-16
CY1106582T1 (el) 2012-01-25
WO2002074232A2 (en) 2002-09-26
HUP0500478A2 (hu) 2005-08-29
CN1536995A (zh) 2004-10-13
WO2002074289A2 (en) 2002-09-26
US6441026B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
DE60218751D1 (de) Antitumor-zusammensetzungen enthaltend taxan-derivate
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
MY134586A (en) Novel pyrroles derivatives as pharmaceutical agents
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
DE60211223D1 (de) Piperidinderivate als Kalium-Kanal Blockers
TW200505890A (en) Breast cancer-resistant protein inhibitor
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
BRPI0213063B8 (pt) composto antibiótico de ação dupla, sua composição farmacêutica e seu uso
ES2243579T3 (es) Derivados de pirazolopirideno.
ATE381328T1 (de) Heterosubstituierte taxan-c10-acetate als antitumormittel
DE69709092D1 (de) Esculetin derivate
CA2218663A1 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
DK0842185T3 (da) Ara-C-derivater
BRPI0412862A (pt) derivados da nicotinamida úteis como inibidores de pde4
AU2002248531A1 (en) Pyrazolopyriadine derivatives
DE60118914D1 (de) Pharmazeutische zusammensetzungen die acryloyl-substituierte distamycin-derivate und topoisomerase i und ii inhibitoren enthalten
WO2004056832A3 (en) Epothilone derivatives
DE60130009D1 (de) Makrolide
ATE432928T1 (de) C10-taxanester als antitumormittel
PL350331A1 (en) C10 carbamoyloxy substituted taxanes as antitumor agents
WO2008015578A3 (en) Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
CA2420056A1 (en) 1-amino-alkylcyclohexanes as trypanocidal agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition